Pharmaceutical Composition For Treating And Preventing Diseases Involving Joints And Connective Tissue

A technology of connective tissue and composition, applied in the direction of drug combination, bone disease, active ingredients of hydroxyl compounds, etc., can solve problems such as long recovery time, cost burden, side effects, etc.

Active Publication Date: 2012-05-30
医药产业园有限公司
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it has various problems including surgical burden, side effects, complications, cost burden and long recovery time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical Composition For Treating And Preventing Diseases Involving Joints And Connective Tissue
  • Pharmaceutical Composition For Treating And Preventing Diseases Involving Joints And Connective Tissue
  • Pharmaceutical Composition For Treating And Preventing Diseases Involving Joints And Connective Tissue

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0100] Example 1: Preparation of Therapeutic Compositions

[0101] The therapeutic compositions shown in Table 1 below were prepared. The components shown in Table 1 were all purchased from Sigma Chemical Co. (USA).

[0102] [Table 1]

[0103]

Embodiment 2

[0104] Embodiment 2: Construction of test animal model

[0105] In this experiment, a rabbit model with a similar structure to the human knee joint was used. Specifically, 11 New Zealand White rabbits (average weight: 3.0±0.01 kg (2.8-2.9 kg), 8-month-old) were used. The reason for using mature rabbits is that osteoarthritis in rabbits is induced under similar conditions to humans, and the ability to regenerate cartilage is lower than that of immature rabbits.

[0106] Eleven rabbits were generally anesthetized and the knee joint of the right hind leg of the rabbit was subjected to cruciate ligament resection, after which the rabbit was left undisturbed for 6 weeks, thereby inducing arthritis in the rabbit.

[0107] Among these test rabbits, 6 rabbits were used as a test group. Six weeks after cruciate ligament resection, the test rabbits were general anesthetized, and then the therapeutic composition of Formulation 2 prepared in Example 1 was injected into the joint cavit...

Embodiment 3

[0110] Example 3: Determination of regeneration and repair of cartilage tissue

[0111] Four weeks after the last injection of the therapeutic composition of Formulation 2 of Example 1, the test rabbits were generally anesthetized and euthanized, and the left and right knee joints were harvested, immersed and fixed in 10% neutral formalin (pH 7.4) 24 hours or more.

[0112] The collected left and right knee joints of the test group and the control group were evaluated by histopathological evaluation method (H&E staining, modified Mankin's scoring method), and the degrees of articular cartilage damage and regeneration were compared between the test group and the control group.

[0113] Also, in order to evaluate the state of the normal left knee articular cartilage (normal group), the state of the right knee cartilage of the test group and the control group was corrected, and then the difference between the groups was statistically evaluated.

[0114] Figures 1 to 4 Shown ar...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a pharmaceutical composition for treating and preventing joint-related diseases and connective-tissue-related diseases, wherein the pharmaceutical composition comprises two or more elements selected from a group consisting of polyol, an amino acid, ornithine, nucleic acid and vitamin C. The pharmaceutical composition of the present invention treats and prevents new arthritis, joint damage and connective tissue diseases in an effective and economical manner without adverse side effects, complications, or the like.

Description

technical field [0001] The present invention relates to the treatment (especially non-surgical treatment) of articular cartilage diseases, diseases of connective tissues including collagen, injuries of joints and connective tissues, and degenerative diseases of intervertebral discs in mammals. Background technique [0002] Collagen is a hard protein found in animal bones, cartilage, teeth, skin, etc., and exists as a fibrous solid. It contains amino acids including proline, hydroxyproline, glycine, glutamine, etc., and is characterized by a high content of hydroxyproline not found in other proteins. Furthermore, hydroxyproline contains hydroxyl groups which play an important role in wetting and elasticity. [0003] Type I collagen consists of two alpha-1(I) polypeptide chains and one alpha-2 polypeptide chain, and is found mostly in skin tissue, bone tissue and the cornea of ​​the eye. Type II collagen consists of three alpha-1(II) polypeptide chains and is found primarily...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/047A61K31/195A61K31/7068A61P19/02
CPCA61K31/047A61K31/711A61K31/198A61K31/341A61K31/401A61K31/195A61P19/02A61K2300/00
Inventor 李日薰朴宥信
Owner 医药产业园有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap